Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 1 | Diabetology & Metabolic Syndrome

Fig. 1

From: Effects of switching from dipeptidyl peptidase 4 inhibitors to oral semaglutide on oxidative stress and glycemic variability in patients with type 2 diabetes: an open-label, prospective, randomized, multicenter, parallel-group comparison study

Fig. 1

Study protocol. Outpatients with type 2 diabetes mellitus (T2DM) who had been on regular doses of dipeptidyl peptidase 4 inhibitors for at least 12 weeks were randomly assigned to either a maintenance therapy group receiving dipeptidyl peptidase 4 inhibitors or a group whose treatment was switched to oral semaglutide

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us